Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients.

To evaluate improvement in gastrointestinal (GI) symptoms and health-related quality of life (HRQoL) in liver transplant recipients switched from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS). A multicenter, open-label, single-arm study was undertaken in maintenance liver transplant recipients who reported GI complications with MMF therapy. The patients were switched to equimolar doses of EC-MPS at baseline. The primary end point was the change in the Gastrointestinal Symptom Rating Scale (GSRS) total score after 6 to 8 weeks of treatment with EC-MPS. Other key assessments for GI symptoms and HRQoL included the GSRS subscores, the Gastrointestinal Quality of Life Index (GIQLI), the Psychological General Well-Being Index, and the Overall Treatment Effect (OTE). Paired t-test was used to assess the difference in the mean score changes over time. A total of 34 patients were enrolled and switched to equimolar doses of EC-MPS. After 6 to 8 weeks of EC-MPS treatment, mean GSRS total score improved significantly from 2.88 ± 0.66 to 2.10 ± 0.78. Mean improvement in GSRS total score (-0.77 score points; P = .001) exceeded the minimal clinically important difference. Significant improvements were observed in all GSRS subscales (P < .05), GIQLI total scores (P = .001), and GIQLI subscales "GI symptoms" (P < .001) and "physical function" (0.013). Patients who continued EC-MPS reported sustained benefits compared with patients who switched back to MMF after 6 to 8 weeks of treatment with EC-MPS. On the OTE scale, improvement in symptoms was reported in 76.5% and 61.8% of the patients as perceived by the physicians and the patients. Improvement in HRQoL was reported by 41.2% of the patients. No deaths, biopsy proven acute rejections, or graft losses were reported during the study. Conversion from MMF to EC-MPS was associated with a significant improvement in GI symptoms and HRQoL in liver transplant recipients.

Sterneck M ，Settmacher U ，Ganten T ，Sarrazin C ，Speidel N ，Broering D ，Heyne N ，Paulus E ，Mertens M ，Fischer L ... -  《-》

Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.

Chan L ，Mulgaonkar S ，Walker R ，Arns W ，Ambühl P ，Schiavelli R ... -  《TRANSPLANTATION》

Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.

Darji P ，Vijayaraghavan R ，Thiagarajan CM ，Sharma RK ，Subbarao B ，Pishardy R ，Dakshinamurthy KV ，Vijaykumar R ，Abraham G ，Bhaskar S ，Agarwal L ，Shah B ，Abraham A ，John M ，Sampathkumar K ，Das T ，Umesh L ，Sundar S ，Ballal H ，Jasuja S ，Saxena S ，Saha TK ... -  《TRANSPLANTATION PROCEEDINGS》

Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.

Hwang HS ，Hyoung BJ ，Kim S ，Oh HY ，Kim YS ，Kim JK ，Kim YH ，Kim YL ，Kim CD ，Shin GT ，Yang CW ... -  《-》

Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.

Ortega F ，Sánchez-Fructuoso A ，Cruzado JM ，Gómez-Alamillo JC ，Alarcón A ，Pallardó L ，Morales JM ，Oliver J ，Guinea G ，MYVIDA Study Group ... -  《-》